Protagenic Therapeutics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

CEO

Protagenic Therapeutics heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Garo Armen	Co-Founder & Executive Chairman of the Board	no data	geen gegevens	16.53% $ 449.0k
Robert Stein	Chief Medical Officer & Director	8.8yrs	geen gegevens	geen gegevens
Timothy Wright	Independent Director	2yrs	geen gegevens	geen gegevens
Brian Corvese	Independent Director	7.3yrs	US$118.75k	geen gegevens
Khalil Barrage	Independent Director	no data	US$243.75k	3.38% $ 91.7k
Jennifer Buell	Independent Director	4.3yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PTIX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Protagenic Therapeutics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Recent updates

Protagenic Therapeutics Receives A Delist Determination Letter from the Nasdaq

New major risk - Financial position

Protagenic Therapeutics, Inc. announced that it expects to receive $1.275 million in funding

Protagenic Therapeutics, Inc. Receives A Deficiency Letter from the Nasdaq Listing Qualifications Regarding Minimum Bid Price Requirement

New minor risk - Shareholder dilution

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Set Forth in Nasdaq Listing Rule 5550(b)(1)

Protagenic Therapeutics, Inc. Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial

New major risk - Share price stability

New major risk - Financial position

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

New major risk - Share price stability

Protagonist Therapeutics, Inc. Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Protagenic Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirements Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

New minor risk - Shareholder dilution

Protagenic Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Share price stability

Protagenic Therapeutics, Inc. Appoints Timothy R. Wright as a Class I Director

Protagenic Therapeutics, Inc., Annual General Meeting, Nov 23, 2022

Protagenic Therapeutics, Inc. announced delayed annual 10-K filing

Protagenic Therapeutics, Inc's Common Stock Deleted from Other OTC

Protagenic Therapeutics, Inc. has completed a Composite Units Offering in the amount of $13.197 million.

Protagenic Therapeutics, Inc. Announces Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Protagenic Therapeutics, Inc. announced that it has received $2 million in funding

Protagenic Therapeutics, Inc. announced that it has received $0.4275 million in funding

Protagenic Therapeutics, Inc. announced that it expects to receive $0.475 million in funding

CEO

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd